filamin A interacting protein 1 likeGenealiases: DOC-1 · DOC1 · GIP130 · GIP90
Q-omics provides the consensus-scored FILIP1L profile across patient tissues and cancer cell-line models. FILIP1L expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, FILIP1L is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, FILIP1L protein abundance shows 23,717 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, BLCA, and LSCC as cancer lineages where FILIP1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FILIP1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FILIP1L survival associations across molecular data types. FILIP1L RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FILIP1L RNA expression–survival associations across cancer types. High FILIP1L expression shows unfavorable associations in MESO, UVM, BLCA and LGG, but favorable associations in HNSC and KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for FILIP1L RNA expression.
This table summarizes FILIP1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FILIP1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FILIP1L shows lower tumor expression in BLCA, KICH, LUSC, UCEC and BRCA and higher tumor expression in HNSC. The BLCA box plot shows higher FILIP1L RNA expression in normal versus tumor tissue (log2 FC = −2.918, t-test p < 0.001).
This table shows molecular features associated with FILIP1L in patient tissues and cancer cell lines. In patient samples, FILIP1L shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FILIP1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
